Euroopa Liit - portugali - EMA (European Medicines Agency)

valneva sweden ab - recombinante a subunidade b da toxina do cólera, o vibrio cholerae 01 - cholera; immunization - vacinas - dukoral é indicado para imunização ativa contra doenças causadas pelo serogrupo o1 de vibrio cholerae em adultos e crianças de 2 anos de idade que visitarão áreas endêmicas / epidêmicas. o uso de dukoral deve ser determinada com base nas recomendações oficiais, levando em consideração a variabilidade da epidemiologia e o risco de contrair a doença em diferentes áreas geográficas e condições de viagem. dukoral não deve substituir o padrão de medidas de proteção. em caso de diarreia medidas de reidratação deve ser instituída.

Brasiilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - vacina covid-19 (recombinante) - vacinas

Brasiilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

achÉ laboratÓrios farmacÊuticos s.a - alfainterferona 2b - imunomodulador

Brasiilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

chron epigen indÚstria e comÉrcio ltda - interferon alfa 2a - antineoplasico

Euroopa Liit - portugali - EMA (European Medicines Agency)

intervet international b.v. - herpesvírus de peru recombinante vivo associado a células (cepa hvt / ilt-138), expressando as glicoproteínas gd e gi do vírus da laringotraqueíte infecciosa - imunológicos para aves, ao vivo viral vacinas - frango - para a imunização ativa de pintos de um dia para reduzir a mortalidade, sinais clínicos e lesões por infecção com o vírus da laringotraqueíte infecciosa aviária (ilt) eo vírus da doença de marek (md).

Euroopa Liit - portugali - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunológicos para suidae - suínos (para engorda) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Euroopa Liit - portugali - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunológicos para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - portugali - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunológicos para felidae, - gatos - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Euroopa Liit - portugali - EMA (European Medicines Agency)

biomarin international limited - recombinant human n-acetylgalactosamine-6-sulfatase - mucopolissacaridose iv - outro aparelho digestivo e metabolismo produtos, - vimizim está indicado para o tratamento de mucopolissacaridose, tipo iva (síndrome de morquio a, mps iva) em pacientes de todas as idades.

Euroopa Liit - portugali - EMA (European Medicines Agency)

zoetis belgium sa - circovirus suíno vacina (vacina inativada, recombinante) - immunologicals for suidae, inactivated viral vaccines - suínos (para engorda) - para imunização ativa de porcos a partir de 3 semanas de idade contra circovírus porcino tipo 2 (pcv2) para reduzir a carga viral no sangue e nos tecidos linfóides e derramamento fecal causado por infecção com pcv2.